Matthew Ho

11PUBLICATIONS

45CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyOther education not elsewhere classifiedMedical infection agents (incl. prions)Respiratory diseases

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|May 15, 2026

Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.

|Jan 15, 2026

CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy.

Matthew Ho, Luca Paruzzo, Julia Han Noll

|Nov 04, 2025

Outcomes of relapse after teclistamab therapy in multiple myeloma.

Kyle L Yu, Matthew Ho, Luca Paruzzo

|Aug 07, 2023

Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.

Matthew Ho, Saurabh Zanwar, Jonas Paludo

|Nov 30, 2022

Hiding in Plain Sight.

Jwan A Naser, Delvise Fogwe, Matthew Ho

|Oct 13, 2022

Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis.

Matthew Ho, Saurabh Zanwar, Francis K Buadi

Pageof 2

Frequent Collaborators

Saurabh Zanwar

Marco Ruella

Federico Stella

Dan T Vogl

Giada Bianchi

Morie Gertz

Angela Dispenzieri

Nelson Leung

S Vincent Rajkumar

Shaji Kumar

Frequent Collaborators

Saurabh Zanwar

Marco Ruella

Federico Stella

Dan T Vogl